NDAORALTABLET
Approved
Sep 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OJJAARA (momelotinib) is an oral small-molecule JAK inhibitor approved by the FDA in September 2023 for myelofibrosis, a rare blood disorder characterized by bone marrow fibrosis and abnormal blood cell production. The drug targets JAK1/JAK2 pathways to reduce spleen enlargement and improve symptom burden in patients with intermediate or high-risk disease.
$0.027BPart D
Peak14.2 years to LOEEarly-stage product in peak commercial phase with growing adoption; GSK is building out sales and marketing infrastructure for orphan/rare disease segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis
Started Nov 2026
40 enrolled
Myelofibrosis
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
Started Aug 2026
268 enrolled
MyelofibrosisMyelofibrosis (MF)
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Started Aug 2026
136 enrolled
VEXAS Syndrome
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
Started Mar 2026
18 enrolled
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromesMyeloproliferative Overlap Neoplasms+1 more
Momelotinib During and After HCT in Myelofibrosis
Started Feb 2026
28 enrolled
MyelofibrosisHematopoietic Cell Transplantation (HCT)
Worked on OJJAARA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.